Response Biomedical Receives Chinese Clearance for Ramp 200 | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Response Biomedical announced on Thursday that China's State Food & Drug Administration has approved its Ramp 200 Reader for marketing in China.

In a statement, Response Biomedical CEO S. Wayne Kay called the approval "a pivotal step forward in increasing our market penetration in this region."

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Biomedical research projects are generating a ton of data that still needs to be analyzed, NPR reports.

Theranos is retiring some of its board members, including Henry Kissinger and George Shultz, Business Insider reports.

The heads of 29 scientific societies and some 2,300 researchers call on President-elect Donald Trump to rely on and support science in two separate letters.

In Science this week: genetically modified flu virus could be key to new live vaccines, and more.